Endocare plans Nitinol urinary stent trials:
This article was originally published in Clinica
Executive Summary
Endocare has applied for an IDE to begin human trials in the US with Horizon, a stenting device to give temporary relief of bladder obstruction in benign prostatic hyperplasia sufferers. The stent is made of the 'memory metal' Nitinol, so that the physician can insert it painlessly into a prosthetic urethra, where it expands and holds the duct open. Endocare expects it will relieve BPH-related acute urinary retention for up to 30 days. The company, of Irvine, California, is also developing a temperature-sensitive version intended for long-term use.
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.